NCT00316563View on ClinicalTrials.gov

Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

November 30, 2009

Conditions

CancerAnorexiaTaste DisordersOlfactory Disorders

Interventions

DRUG

Marinol (Dronabinol)

Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.

OTHER

Placebo

Trial Locations (2)

T6G 1Z2

Cross Cancer Institute, Edmonton

H2W 1S6

Royal Victoria Hospital, Montreal

All Listed Sponsors

collaborator

University of Alberta

OTHER

lead

Alberta Health services

OTHER

NCT00316563 - Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study | Biotech Hunter | Biotech Hunter